Sequent Scientific Ltd Annually Results

192.65
(-1.92%)
Dec 9, 2024|03:31:00 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

1,369.73

1,420.91

1,412.82

1,361.62

1,179.24

Excise Duty

0

0

0

0

0

Net Sales

1,369.73

1,420.91

1,412.82

1,361.62

1,179.24

Other Operating Income

0

0

0

0

0

Other Income

10.96

6.39

10.85

8.36

10.09

Total Income

1,380.69

1,427.3

1,423.66

1,369.98

1,189.33

Total Expenditure

1,325.71

1,473.75

1,303.42

1,158.37

1,008.92

PBIDT

54.98

-46.45

120.25

211.61

180.41

Interest

48.09

35.52

15.77

24.38

35.71

PBDT

6.89

-81.97

104.47

187.23

144.7

Depreciation

61.54

55.69

51.54

50.6

50.62

Minority Interest Before NP

0

0

0

0

0

Tax

13.95

7.52

13.7

35.04

22.51

Deferred Tax

-38.98

-23.2

-5.53

-2.86

-10.48

Reported Profit After Tax

-29.62

-121.98

44.76

104.45

82.05

Minority Interest After NP

6.26

-0.82

3.81

9.01

12.14

Net Profit after Minority Interest

-35.88

-121.16

40.96

95.44

69.91

Extra-ordinary Items

-12.95

-61.26

0

-6.56

0

Adjusted Profit After Extra-ordinary item

-22.93

-59.9

40.96

102

69.91

EPS (Unit Curr.)

-1.44

-4.88

1.65

3.87

2.87

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

0

0

0

25

0

Equity

49.89

49.89

49.67

49.67

49.67

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

4.01

-3.26

8.51

15.54

15.29

PBDTM(%)

0.5

-5.76

7.39

13.75

12.27

PATM(%)

-2.16

-8.58

3.16

7.67

6.95

Sequent Scien.: Related NEWS

Sequent Scientific jumps ~12% on ₹8,000 Crore merger with Viyash Life
27 Sep 2024|03:01 PM

Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp